^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GLSI-100

    i
    Associations
    News

    Trials

    Company:
    Greenwich LifeSci
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects (FLAMINGO-01) (NCT05232916)
    Phase 3
    Greenwich LifeSciences, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/11/2022
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2 • HLA-A
    |
    HLA-A*02 positive
    |
    Herceptin (trastuzumab) • GLSI-100 • GP2
    Vaccine Therapy in Treating Patients With Breast Cancer (BAMC-C.2007.098) (NCT00524277)
    Phase 2
    San Antonio Military Medical Center
    Completed
    Last update posted :
    03/30/2020
    Initiation :
    01/01/2007
    Primary completion :
    12/31/2014
    Completion :
    03/31/2017
    HER-2 • ER • PGR • CSF2
    |
    HER-2 amplification • HER-2 expression • HLA-A2 positive • PGR negative
    |
    AE 37 • GLSI-100 • Leukine (sargramostim)
    Immunotherapy Vaccine and Herceptin in Breast Cancer (NCT03014076)
    Phase 1
    Cancer Insight, LLC
    Completed
    Last update posted :
    01/09/2017
    Initiation :
    01/01/2008
    Primary completion :
    01/01/2016
    Completion :
    01/01/2017
    HER-2
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • GLSI-100